Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00361283 · ClinicalTrials.gov registry record · Phase 4
Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis
A Phase 4 study of Inflammation, sponsored by University of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 108
- Enrollment target
- 1
- Study location
NCT00361283 is a Phase 4 study of Inflammation that has completed, run by University of Florida. The registered enrollment target is 108 participants, below the 287-participant average among 132 other Inflammation trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00361283, a Phase 4 study of Inflammation, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 108 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to test whether atorvastatin (also known as Lipitor) has anti-inflammatory effects in people with no known heart disease or high cholesterol. We also are investigating whether or not genetic differences between people plays a role in the drug response.
Conditions Studied
Interventions
- DRUG Atorvastatin
Study Locations (1)
Florida
- University of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2004-06 |
| Est. Completion | 2009-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00361283
The ClinicalTrials.gov registry entry for NCT00361283 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 287-participant average among 132 other Inflammation trials with a reported enrollment target (62% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Inflammation appearing as the primary indexed condition, and to 1 intervention - of which Atorvastatin is the first listed.
NCT00361283 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT00361283 about?
NCT00361283 is a clinical study titled "Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis". The purpose of the study is to test whether atorvastatin (also known as Lipitor) has anti-inflammatory effects in people with no known heart disease or high cholesterol. We also are investigating whether or not genetic differences between people plays a role in the drug response.
What is the current status of trial NCT00361283?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 108 participants. The study started on 2004-06. Estimated completion is 2009-01.
What conditions does trial NCT00361283 study?
This clinical trial studies the following conditions: Inflammation.
What interventions are being tested in trial NCT00361283?
The interventions under investigation include: Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00361283?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00361283 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Skin Barrier Function and Inflammation in Aging: The BIA Study
RECRUITING · Phase 4
-
Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes
COMPLETED · Phase 4
-
Impact of Ascorbic Acid on Post-Cardiothoracic Surgery Inflammation
COMPLETED · Phase 4
-
Efficacy of Ketorolac 0.4% in Prostaglandin Suppression
COMPLETED · Phase 4
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.